Figure 4 | Scientific Reports

Figure 4

From: Circulating cell death biomarker: good candidates of prognostic indicator for patients with hepatitis B virus related acute-on-chronic liver failure

Figure 4

Serial measurements of M30-antigen and M65-antigen in a subset of HBV-ACLF patients.

Seral M30-antigen (A) and M65-antigen (B) from 6 survivors and 8 non-survivors were measured upon diagnosis and 1, 2, 4 weeks after diagnosis. Results were presented as the mean ± SEM. Changes in M30-antigen, M65-antigen and the apoptosis rate (M30/M65) were shown as a percentage of day 1 values. The upper right panel (C) showed the mean changes in M30-antigen, M65-antigen and M30/M65 in the 6 survivors with HBV-ACLF, in which the M65-antigen remained relatively constant during the first 4 weeks while the M30-antigen and apoptosis rate continually increased. The lower right (D) panel showed a representative example of a non-survival HBV-ACLF patient with a slightly increased apoptosis rate at week 1 and a decline at week 2 and week 4.

Back to article page